CytoDyn Swaps CEOs: CFO Hoffman Takes the Helm as Lalezari Moves to Research
CYDY sits 37% above its 52-week low of $0.183 on elevated volume (3.8× avg).
Summary
CytoDyn named CFO Robert Hoffman CEO effective October 20, 2026, with Dr. Jacob Lalezari stepping down to a research role. The same filing carries an investor webcast with preliminary CLOVER colorectal cancer data showing deep ctDNA declines in a small patient set.
Key Events · Executive and Board Changes · CYDY
-
CFO Hoffman Named CEO
The board appointed Robert E. Hoffman CEO effective October 20, 2026, and he retains the principal accounting officer role. Dr. Jacob Lalezari resigned as CEO the same day and becomes Head of Research and Translational Sciences under a new employment agreement with no change in compensation.
-
New CEO Pay Package
Base salary rises to $525,000 and the bonus target from 40% to 50%. Hoffman receives 2.5M options struck at the higher of the October 16 and October 20 closing prices, vesting 25% on October 16, 2027 and the rest monthly through October 16, 2030.
-
Preliminary CLOVER Data Disclosed
Webcast slides report 38 of 51 (74.5%) evaluable patients with week-8 scans showing tumor shrinkage or stable disease, a median 86% ctDNA decline at week 2 across 28 patients, no leronlimab-related serious adverse events, and three patients referred for curative-intent surgery. These are a preliminary cut, with 22 of 65 subjects (34%) still on study.
-
Next Data Readout at ESMO
Additional CLOVER clinical and ctDNA findings are scheduled for ESMO in Madrid, October 23-27, 2026, with further updates at ASCO GI, January 21-23, 2027. The company also targets an mTNBC dose-escalation study start in the fourth quarter of 2026.
Analysis · CYDY · Life Sciences
At a clinical-stage company carrying a going-concern warning, a CEO change is a genuine governance event, not a formality. Lalezari had been the public face of leronlimab for years; handing the top job to the CFO — who keeps the principal accounting officer title — puts financial discipline and capital raising ahead of scientific promotion at precisely the moment CytoDyn needs cash. The 2.5M option grant and the salary bump to $525,000 are modest in dollar terms, but they tie the new CEO to a stock trading around $0.25. The bigger swing factor sits in the attached webcast: preliminary CLOVER data (74.5% of evaluable patients with shrinkage or stable disease at week 8, median 86% ctDNA decline at week 2 in 28 patients) is encouraging but early, with 34% of subjects still on study and the database not locked. ESMO on October 23-27, 2026 is the next scheduled data update.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYDY was trading at $0.25 on OTC in the Life Sciences sector, with a market capitalization of approximately $367.4M. The 52-week trading range was $0.18 to $0.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.